Aquestive Therapeutics (AQST) vs Eton Pharmaceuticals (ETON)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Aquestive Therapeutics (AQST) over the past year, gaining 161.6% versus a loss of 23.2%. Over five years, ETON leads with a +950.9% price change compared with +23.0% for AQST. Eton Pharmaceuticals is the larger company by market cap ($1.57 billion vs $606.8 million), about 2.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AQST | ETON |
|---|---|---|
| Share price | $4.84 | $54.83 |
| Market cap | $606.85M | $1.57B |
| 1-day change | +1.57% | +0.15% |
| YTD return | -26.32% | +223.77% |
| 1-year return | -23.23% | +161.59% |
| 5-year return | +23.00% | +950.86% |
| P/E ratio (TTM) | — | 137.08 |
| Forward P/E | — | 21.25 |
| EPS (TTM) | $-0.66 | $0.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $79.95M |
| Revenue growth (YoY) | — | +104.94% |
| Net income (latest FY) | — | $-4.60M |
| Gross margin | — | 53.46% |
| Operating margin | — | -1.06% |
| Net margin | — | -5.75% |
| 52-week high | $7.55 | $66.37 |
| 52-week low | $2.93 | $14.27 |
| Distance from 52-week high | -35.96% | -17.39% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +92.97% | +29.49% |
| Average volume | 2.68M | 609.36K |
| Shares outstanding | 125.51M | 28.58M |
| Employees | 147 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Eton Pharmaceuticals is about 2.6 times larger than Aquestive Therapeutics by market value ($1.57B vs $606.85M).
- ETON has outperformed AQST by 184.8 percentage points over the past year.
About Aquestive Therapeutics
AQST stock →Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
AQST vs ETON FAQ
Which is bigger, Aquestive Therapeutics or Eton Pharmaceuticals?
Eton Pharmaceuticals (ETON) is larger, with a market capitalization of $1.57B compared with $606.85M for Aquestive Therapeutics (AQST).
Which stock has performed better over the past year, AQST or ETON?
ETON returned +161.59% over the past 12 months, compared with -23.23% for AQST (price return, excluding dividends). Past performance does not predict future results.
Are Aquestive Therapeutics and Eton Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.